

1 **Health impacts of COVID-19 disruptions to primary cervical screening by time since**
2 **last screen: A model-based analysis for current and future disruptions**

3
4 Header: COVID-19 disruptions to routine cervical cancer screening

5
6 **Authors and affiliations**

7 Emily A. Burger, Inge M.C.M. de Kok*, James F O'Mahony*, Matejka Rebolj, Erik E. L. Jansen, Daniel
8 D. de Bondt, James Killen, Sharon Hanley, Alejandra Castanon, Jane J. Kim, Karen Canfell, Megan
9 A. Smith

10
11 * contributed equally, listed alphabetically

12
13 **Corresponding author:**

14 Emily A. Burger
15 Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Boston, MA, USA
16 718 Huntington Ave, 2nd Floor
17 Boston, MA 02115
18 617.432.0190
19 Department of Health Management and Health Economics, University of Oslo, Oslo, Norway
20 eburger@hsph.harvard.edu

21
22
23 **Author information**

24
25 Inge M.C.M. de Kok*
26 Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The
27 Netherlands
28 i.dekok@erasmusmc.nl

29
30 James F O'Mahony*
31 Centre for Health Policy & Management, School of Medicine, Trinity College Dublin, Dublin, Ireland
32 Jfomahon@tcd.ie

33
34 Matejka Rebolj
35 King's College London, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical
36 Sciences, London, United Kingdom
37 matejka.rebolj@kcl.ac.uk

38
39 Erik E.L. Jansen
40 Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The
41 Netherlands
42 e.e.l.jansen@erasmusmc.nl

43
44 James Killen
45 Cancer Research Division, Cancer Council NSW, Sydney, Australia
46 James.Killen@nswcc.org.au

47
48 Daniel D. de Bondt
49 Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The
50 Netherlands
51 d.debondt@erasmusmc.nl

52
53 Sharon J. Hanley
54 Department of Obstetrics and Gynaecology, Hokkaido University, Sapporo, Japan
55 sjbh1810@med.hokudai.ac.jp

56
57 Alejandra Castanon
58 King's College London, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical
59 Sciences, London, United Kingdom
60 alejandra.castanon@kcl.ac.uk

61 Mary Caroline Regan
62 Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Boston, MA, USA
63 mregan@hsph.harvard.edu F
64
65 Jane J. Kim
66 Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Boston, MA, USA
67 jkim@hsph.harvard.edu
68
69 Karen Canfell
70 Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
71 karen.canfell@nswcc.org.au
72
73 Megan A. Smith
74 Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
75 megan.smith@nswcc.org.au
76
77

78 ABSTRACT

79

80 **Background.** We evaluated how temporary disruptions to primary cervical cancer (CC) screening
81 services may differentially impact women due to heterogeneity in their screening history and test
82 modality.

83

84 **Methods.**

85 We used three CC models to project the short- and long-term health impacts assuming an underlying
86 primary screening frequency (i.e., 1, 3, 5, or 10 yearly) under three alternative COVID-19-related
87 screening disruption scenarios (i.e., 1-, 2- or 5-year delay) versus no delay, in the context of both
88 cytology-based and HPV-based screening.

89

90 **Results.** Models projected a relative increase in symptomatically-detected cancer cases during a 1-
91 year delay period that was 38% higher (Policy1-Cervix), 80% higher (Harvard) and 170% higher
92 (MISCAN-Cervix) for under-screened women whose last cytology screen was 5 years prior to the
93 disruption period compared with guidelines-compliant women (i.e., last screen three years prior to
94 disruption). Over a woman's lifetime, temporary COVID-19-related delays had less impact on lifetime
95 risk of developing CC than screening frequency and test modality; however, CC risks increased
96 disproportionately the longer time had elapsed since a woman's last screen at the time of the
97 disruption. Excess risks for a given delay period were generally lower for HPV-based screeners than
98 for cytology-based screeners

99

100 **Conclusions.** Our independent models predicted that the main drivers of CC risk were screening
101 frequency and screening modality, and the overall impact of disruptions from the pandemic on CC
102 outcomes may be small. However, screening disruptions disproportionately affect under-screened
103 women, underpinning the importance of reaching such women as a critical area of focus, regardless
104 of temporary disruptions.

105

106 **Funding.** This study was supported by funding from the National Cancer Institute (U01CA199334).
107 The contents are solely the responsibility of the authors and do not necessarily represent the official
108 views of the National Cancer Institute. Megan A Smith receives salary support from the National
109 Health and Medical Research Council, Australia (APP1159491) and Cancer Institute NSW
110 (ECF181561). Matejka Rebolj is funded by Cancer Research UK (reference: C8162/A27047). James
111 O'Mahony is funded by Ireland's Health Research Board (EIA2017054). Karen Canfell receives salary
112 support from the National Health and Medical Research Council, Australia (APP1194679). Emily A.
113 Burger receives salary support from the Norwegian Cancer Society.

114 INTRODUCTION

115

116 The coronavirus disease 2019 (COVID-19) pandemic continues to impact on a wide range of health
117 outcomes. In the initial months of the pandemic in 2020, there were severe disruptions to
118 preventive services including cervical cancer screening. For example, during acute phases of the
119 pandemic in the United States (U.S.), 59% of federally qualified health centers stopped cancer
120 screenings completely (1), and electronic health records from 39 organizations spanning 23 States
121 found a 67% decline in mean weekly cervical cancer screening volumes (2). While cancer screening
122 volumes gradually improved (2), mid-June 2020 volumes remained around 30% lower than their pre-
123 COVID-19 levels, and cervical volumes have remained 10% lower two years into the pandemic (3).

124

125 The risk of developing cervical cancer depends in part on time since a last screen (4, 5). Despite U.S.
126 recommendations for primary cervical cancer screening of either 3-yearly cytology or 5-yearly HPV
127 testing (6), there is heterogeneity in adherence to guideline-recommendations where both under-
128 screening and over-screening are observed, when comparing behavior to recommendations. For
129 example, in the only population-based registry in the U.S. prior to widespread primary HPV-based
130 screening, 20% of women were not screened within 5 years (7), which was correlated with race and
131 ethnicity, income level, lower levels of education and lack of insurance (8). Conversely, screening
132 more frequently than recommended has been observed in 66% of insured women (9).

133

134 The impact of service disruptions due to COVID-19 may not have affected all women equally. For
135 women without health insurance or unable to access care, or those who avoid care due to fear of
136 COVID-19, the disruptions may continue. In other countries such as the United Kingdom (U.K.), 30%
137 of survey respondents elicited Fall 2020 reported that they were less likely to attend cervical
138 screening now than before the pandemic (10). Although the observed decrease in screening
139 attendance ultimately was smaller than surveyed intentions to screen (11), the U.K. study also found
140 that previous non-participation was the strongest predictor of low intentions for future post-
141 pandemic participation.

142

143 Rebounds towards pre-pandemic attendance levels in aggregate-level metrics may suggest a
144 successful recovery but could actually mask unexpected disparities in coverage. For example, the
145 same disruption period may differentially impact women due to heterogeneity in their screening
146 history so that the impact is greater for those under-screened compared to those that are screened
147 according to recommended guidelines. It will thus be important to understand the influence of
148 variation in women's past behavior as a contributor to underlying risk when assessing past and
149 ongoing disruptions to screening.

150

151 Empirically, decreases in cervical cancer diagnoses in 2020 have been confirmed in the U.S. (12) and
152 elsewhere (13). Previous model-based analyses have projected that temporary disruptions to
153 cervical cancer screening may result in temporal shifts in cancer detection (initial decreases followed
154 by an increase), yielding small net increases in cervical cancer burden (14, 15). Such decreases are to
155 be expected in the short run due to the reduction in screening and related investigations and any net
156 increases will only be observed in time. Model-based analyses (14, 15) have shown that maintaining
157 services for the highest risk women may mitigate the potential secondary impacts of COVID-19 on
158 cervical cancer; for example, prioritizing those in need of surveillance, colposcopies or excisional
159 treatment, as well as women whose last primary screen did not involve a highly sensitive test, such
160 as that for the detection of human papillomavirus (HPV). Furthermore, short delays to cervical
161 screening services among women with a previous negative HPV result had minor effects on cancer
162 outcomes; however, previous analyses have not explicitly stratified outcomes for women by their
163 prior screening history, i.e., time since last screen.

164

165

166 Disease simulation models can help assess the impact of service disruptions and policy responses in
167 advance of empirical data. Models can also quantify health consequences of alternative screening
168 disruption scenarios and isolate complex interactions between temporary screening suspensions for
169 women with different underlying screening histories. These simulations can help inform which
170 women are most vulnerable to COVID-19 disruptions and should be prioritized for targeted recovery
171 activities. Therefore, as part of the Covid and Cancer Global Modelling Consortium (CCGMC), we
172 used three US-contextualized cervical cancer natural history models from the Cancer Intervention
173 and Surveillance Modeling Network (CISNET) consortium (<https://cisnet.cancer.gov/>) to isolate the
174 health impact of temporary disruptions to *primary screening services only* by time since a woman’s
175 last screen and primary screening test modality. Multi-model comparative analyses can demonstrate
176 the validity of findings and test the robustness despite structural differences between the models
177 used. The purpose of this analysis is to provide decision makers with evidence regarding the
178 potential impact of temporary disruptions to the provision of screening services on cervical cancer
179 incidence, either due to the COVID-19 pandemic or any other similar disruption, on a disaggregated
180 basis according to women's prior screening history in order to inform any targeted allocation of
181 scarce screening capacity.

182

183 METHODS

184

185 Analytic overview

186 To complement our previous analysis (14), we used the same three CISNET-Cervical microsimulation
187 models to project the expected lifetime risk (until age 84 years) of developing cervical cancer for
188 three birth cohorts (born in 1965, 1975 and 1985; aged 55, 45 and 35 in 2020, respectively) assuming
189 an underlying exposure to HPV vaccination (see (16)) and screening frequency—that is, annual, 3-
190 yearly, 5-yearly, or 10-yearly screening, aligned so that 2020 was 1, 3, 5, or 10 years since their last
191 screen (**Figure 1; Appendix Tables A1 and A2**). These selected birth cohorts enabled the analysis to
192 capture at least 10 years of pre- and post-COVID-19 screening history. We used the models to
193 estimate both the short- and long-term impacts of COVID-19 delays on cervical cancer burden. As
194 both primary cytology- and HPV-based screening modalities are recommended in the U.S., we
195 explored these outcomes in the context of primary cytology (i.e., Pap smear only) with and without
196 switching to primary high-risk HPV testing from age 30 years with partial genotyping for HPV
197 genotypes 16 and 18. Screen-positive women were managed according to guidelines (17) and
198 followed Kaiser Permanente Northern California compliance patterns, i.e., colposcopy compliance
199 (79%), precancer treatment compliance (73%) (18). Scenarios were simulated in the context of birth
200 cohort-specific historical HPV vaccination coverage as estimated and applied in another analysis (19).


201

202 For the short-term impacts, we estimated the relative excess rate of symptomatically-detected
203 cancer during a COVID-19-related screening delay period for under-screener compared with
204 “guidelines-compliant screeners” (i.e., those who perfectly adhere to 3-year cytology screening or 5-
205 yearly HPV screening, except for during the Covid-19 disruption period). We averaged the cancer
206 incidence rates (per 100,000 women) accumulated during a delay period (i.e., 1, 2 or 5 years) across
207 the three birth cohorts for each screening history profile (i.e., 3-yearly, 5-yearly or 10-yearly
208 screening). The denominator for each relative rate (RR) calculation was the accumulated cancer rate
209 under a given delay period for a guidelines-compliant screener, which differed according to primary
210 test modality (i.e., 3-yearly screening for cytology-based screeners and 5-yearly screening for HPV-
211 based screeners) (**Appendix Figure A1**). For the long-term impact, we projected the impact of
212 disruptions to lifetime risks and absolute changes in cancer risks for each of the three alternative
213 COVID-19-related screening delay scenarios, compared to a scenario of no COVID-19-related
214 disruptions. To set findings within the wider context of prevention, we additionally considered how
215 much each scenario would reduce a woman’s lifetime risk of developing cervical cancer (compared

216 to a hypothetical no screening scenario). For each scenario, model projections of cervical cancer
217 cases and lifetime risks were averaged across the three birth cohorts.

218

219 **Figure 1. Scenario overview reflecting the heterogeneity in screening history (aligned so that 2020**
220 **was 1, 3, 5, or 10 years since their last screen) facing alternative COVID-19 delay disruptions for**
221 **three birth cohorts of women.**



* Guidelines based screener for cytology-based screening

** Guidelines-based screener for human papillomavirus (HPV)-based screening

222

223 **Simulation models**

224 As previously described (14, 20, 21), the three CISNET-Cervical models (Harvard, MISCAN-Cervix and
225 Policy1-Cervix) reflect the natural history of HPV-induced cervical cancer but differ structurally with
226 respect to the type and number of health states, HPV genotype categorizations, histological cancer
227 types, model cycle length and data sources used to parameterize the model prior to fitting to the
228 U.S. population. Standardized US-model inputs included hysterectomy rates, all-cause mortality, and
229 cervical cancer survival (20). To reflect the burden of HPV and cervical cancer in the U.S., the models
230 were calibrated to HPV and cervical disease outcomes, achieving good fit to empirical targets based
231 on U.S. women (See Burger et al 2020 (20) for details of the calibration and fitting processes).

232

233 **Scenarios and assumptions**

234 We assumed that in the absence of the COVID-19 pandemic, each cohort would have received a
235 primary cervical screen in 2020, aligned with an underlying screening frequency, i.e., 1, 3, 5, or 10
236 years since the last screen. For each birth cohort and screening frequency combination, these
237 women faced either no delay, or a 1-, 2- or 5-year delay (**Figure 1, Appendix Table A2**). We assumed
238 that during the delay period, there was a 100% temporary loss in primary screening, but following


239 the delay period, screening was assumed to immediately resume, and women would continue to
 240 follow their pre-pandemic screening frequency. We assumed COVID-19 did not impact attendance
 241 for surveillance, diagnosis, or treatment of screen-detected abnormalities or investigation for
 242 symptomatically-detected cancers, except when directly implied by missed screening events during a
 243 COVID-19 delay period. In line with U.S. guideline recommendations, all models assumed women did
 244 not attend for routine screening after age 65 years. A key modifier of the impact of screening delays
 245 on lifetime risk is the age at which women received their last screening test (22). Due to the
 246 analytically fixed screening intervals assumed post-COVID-19-related delay, the timing of future
 247 screening was shifted in all cohorts other than annual screeners; as a result, for some combinations
 248 of screening frequency and COVID-19-related delays, the delays also reduced the number of lifetime
 249 screens and/or changed the age at last screen (**See Appendix Tables A1 and A2 for additional**
 250 **details**). For example, for a woman born in 1975 who screens every 10 years, her last screen would
 251 be at age 65 years without a COVID-19 disruption; however, her last screen would occur at age 56,
 252 57 or 60 under the 1-, 2- or 5-year delay scenarios.

253 RESULTS

254 Short-term impacts

255 On average, among women aged 35-55 years, the models projected a relative increase in
 256 symptomatically-detected cancer burden during a 1-year delay period that were higher – 38% higher
 257 (Policy1-Cervix), 80% higher (Harvard) and 170% higher (MISCAN-Cervix) – for those who had not
 258 screened in 5 years at the time of the disruption, compared with women who attended cytology-
 259 based screening according to guidelines (i.e., every three years) (**Figure 2; left panels**). Compared
 260 with guidelines-compliant cytology screeners, the relative excess burden of cancers detected during
 261 a 1-year delay period was 3.1 (Policy1-Cervix), 3.2 (Harvard), or 7.0 (MISCAN-Cervix) times higher for
 262 women whose last cytology screen was 10 years ago at the time of the disruption. Compared with
 263 women who switched to HPV-based screening at age 30 and were guidelines-compliant screening
 264 every 5 years, women who screened every 10 years with HPV after age 30 years faced an excess
 265 cancer burden that was generally consistent regardless of the disruption period, ranging from 2.2-
 266 2.5 (Policy1-Cervix), 3.0-3.9 (MISCAN-Cervix), and 3.6-3.7 (Harvard) times higher (**Figure 2; right**
 267 **panels**). Although the relative excess burden among women overdue for screening remained
 268 generally similar by delay period, the absolute accumulated rates increased with the length of the
 269 delay period (**Appendix Table A3**).

270 **Figure 2. Short-term impacts: Relative rate ratio of cancer detected during the screening delay**
 271 **period for under-screeners compared with the same delay duration for guidelines-compliant**
 272 **screeners.**



277

278


279

280 *Long-term impacts*

281 The models consistently projected that a 1- or even 5-year temporary disruption to primary
 282 screening had a smaller effect on the lifetime risk of developing cervical cancer than the effects from
 283 screening frequency and modality we considered (**Figure 3**). For example, within-model comparisons
 284 found that the lifetime risk of developing cervical cancer was lower, even in the context of an
 285 extreme 5-year screening disruption, for women screened every 3 years with cytology prior to the
 286 disruption (Policy1-Cervix (0.21%) Harvard (0.32%), and MISCAN-Cervix (0.32%)) than for women
 287 screening every 5 years without a disruption (Policy1-Cervix (0.22%), Harvard (0.42%), and MISCAN-
 288 Cervix (0.39%)) (**Figure 3, upper panels**). Set within the wider context of prevention, the models
 289 projected that, under an extreme scenario of a 5-year delay, 3-yearly cytology screening maintained
 290 nearly all benefits of screening, decreasing from preventing 72.1% to 69.1% (MISCAN-Cervix), 79.9%
 291 to 78.4% (Harvard), and 86.5% to 85.1% (Policy1-Cervix) of cancer cases over a woman’s lifetime
 292 compared with no screening (assuming screening resumed following the disruption) (**Appendix**
 293 **Table A4**). In contrast to women screened with cytology over their lifetime, women screened with
 294 primary HPV after age 30 years face a lower overall lifetime risk of cervical cancer (and percentage of
 295 cancers prevented by screening was higher) compared with cytology-based screening; furthermore,
 296 these women generally faced smaller impacts of a COVID-19 disruption to screening relative to
 297 screening frequency (**Figure 3, right panel; Appendix Figure A4**).

298

299 **Figure 3. Long-term impacts: Projected impact of COVID-19-related disruptions to primary cervical**
 300 **cancer screening on the lifetime risk of developing cervical cancer (averaged across the**
 301 **1965/1975/1985 birth cohorts of women) by time since last screen for cytology-based screening**
 302 **(top panels) and human papillomavirus (HPV)-based screening (bottom panels) for three CISNET-**



303 **Cervical disease simulation models.**

304


305

306 Despite the relatively lower contribution of COVID-19-related delays to lifetime risk of developing
 307 cervical cancer than screening frequency and test modality, there were important differences in the
 308 impact of a delay period on a woman’s lifetime risk by the length of time since her last screen and
 309 the screening modality used during the last screen (**Figure 4**). In general, annual or 3-yearly

310 screeners faced only nominal excess risks when experiencing a 1-year temporary delay to primary
 311 cytology screening, and cancer risks increased disproportionately the longer time had elapsed since
 312 a woman’s last screen (**Figure 4; upper panels**). For example, all models projected that compared
 313 with no COVID-19 delay, an extreme 5-year temporary delay scenario was expected to increase the
 314 number of remaining lifetime cervical cancer cases by 20 (Policy1-Cervix), 22 (Harvard), and 31
 315 (MISCAN-Cervix) per 100,000 women screened 3-yearly with cytology, compared to an increase of
 316 44 (Harvard), 47 (MISCAN-Cervix), and 66 (Policy1-Cervix) per 100,000 women screened 10-yearly
 317 with cytology (**Table 1**). Importantly, these excess risks for a given delay period were generally lower
 318 for HPV-based screeners than for cytology-based screeners (**Figure 4; lower panels**). For example,
 319 compared with cytology-based screening, two of the models (Harvard and Policy1-Cervix) found that
 320 woman screened with primary HPV testing faced smaller excess risks for the same delay duration
 321 unless women were screening very infrequently (10-yearly), in which case, the excess risks of cancer
 322 were similar, i.e., 44-66 per 100,000 women for cytology versus 40-58 per 100,000 women for HPV
 323 100,000 women).

324
325
326
327
328
329
330
331

332 **Figure 4. Long-term impacts: Projected impact of COVID-19-related disruptions to primary cervical**
 333 **cancer screening on the incremental lifetime risk of developing cervical cancer (averaged across**
 334 **the 1965/1975/1985 birth cohorts of women) by time since last screen for cytology-based**
 335 **screening (top panels) and human papillomavirus (HPV)-based screening (bottom panels) for three**
 336 **CISNET-Cervical disease simulation models.**



337
338
339
340

341
342
343
344
345
346
347
348
349
350
351
352
353
354
355

Table 1. Long-term health impacts* of a 5-year temporary delay to screening compared with no delay, by screening history, i.e., screening frequency

		Screening frequency			
		Annual	3-yearly	5-yearly	10-yearly**
Primary cytology-based screening					
<i>Harvard</i>					
	Absolute change in lifetime risk	0.008%	0.022%	0.031%	0.044%
	Excess cases over lifetime per 100,000 women	8	22	31	44
<i>MISCAN-Cervix</i>					
	Absolute change in lifetime risk	0.021%	0.031%	0.034%	0.047%
	Excess cases over lifetime per 100,000 women	21	31	34	47
<i>Policy1-Cervix</i>					
	Absolute change in lifetime risk	0.014%	0.020%	0.029%	0.066%
	Excess cases over lifetime per 100,000 women	14	20	28	66
Primary HPV-based screening					
<i>Harvard</i>					
	Absolute change in lifetime risk	0.000%	0.001 %	0.004 %	0.040%
	Excess cases over lifetime per 100,000 women	0	1	4	40
<i>MISCAN-Cervix</i>					
	Absolute change in lifetime risk	0.017 %	0.032%	0.041%	0.063%
	Excess cases over lifetime per 100,000 women	17	32	41	63
<i>Policy1-Cervix</i>					
	Absolute change in lifetime risk	0.000%	0.006%	0.012%	0.058%
	Excess cases over lifetime per 100,000 women	0	6	12	58

356 *Risks are rounded to nearest 0.001%; **The women born in 1985 (aged 35 in 2020) received their last screen
357 at age 25 and have not yet made the switch to primary human papillomavirus (HPV)-based screening. In the

358 primary HPV-based analysis, these women would switch to primary HPV-based screening for their remaining
359 lifetime either at 35 (under the no delay scenario) or aged >35 years (with a delay).

360

361

362 DISCUSSION

363 The results of our comparative health impact modeling study suggest women who are overdue for
364 screening and encounter a further delay face an increased risk of presenting with a symptomatic
365 cancer during the delay period compared with those who attend screening regularly according to
366 guidelines. Furthermore, women who undergo routine guidelines-compliant screening are able to
367 endure a temporary, i.e., 1-year, disruption to cervical screening under both primary cytology and
368 HPV-based screening modalities, and those who undergo guidelines-compliant screening with HPV
369 testing are more resilient to longer delays (2 or 5 years). In the U.S., where there is heterogeneity in
370 screening behavior (9), our findings suggest that to minimize population cancer risk, targeted
371 outreach to over-screened and regularly-screened women should be a lower priority than outreach
372 to women whose screening history is not up-to-date. Our findings support outreach to women most
373 vulnerable to COVID-19 disruptions who also faced pre-pandemic barriers to routine screening.
374 Importantly, aggregated metrics demonstrating a near-return to pre-pandemic screening volumes
375 may not be adequate to capture heterogeneities in screening history, and therefore, risk associated
376 with disruptions to screening.

377

378 Similar to our previous results (14), we found that screening with primary HPV testing generally
379 provided greater reductions to lifetime risk of developing cervical cancer compared with cytology-
380 based screening. Although we did not explicitly simulate screening that switches from cytology-
381 based screening before a disruption to HPV testing upon resumption such a strategy may be able to
382 mitigate any pandemic-related excess risks. Similarly, we found that the impact of disrupting an HPV-
383 based screening program has different implications than the disruption of a cytology-based program.
384 This can be explained by the fact that HPV screening has a higher sensitivity to detect (pre-invasive)
385 cervical lesions; therefore, the cancer risk at time of disruption is lower and this may provide a
386 greater buffer to endure temporary disruptions. On the other hand, in case of the more sensitive
387 HPV test, disruption takes away a relatively more valuable screening moment. The balance between
388 these two factors causes a greater or smaller excess risk per delay duration in case of HPV screening
389 compared to cytology screening. If in a model the first effect is larger than the second effect,
390 disruption of the HPV program has a smaller effect than of the cytology program, which is the case
391 for all screening frequencies in both the Harvard and Policy1-cervix models and the annual screeners
392 in MISCAN-cervix. The MISCAN-Cervix model predicted relatively more excess cancers for women
393 screened with HPV 3-yearly, 5-yearly or 10-yearly due to disruptions, where the second factor seems
394 to outweigh the first. Differences in dwell time for HPV and cervical precancer among the three
395 models contributes to this balance between the two factors (**Appendix**), where the MISCAN-Cervix
396 model has the shortest preclinical dwell time from HPV acquisition to cancer development (20). In
397 addition to the shorter dwelling times, the MISCAN model also assumes that some precancerous
398 lesions are structurally missed over time by cytology-based screening because they are located
399 deeper into the cervical canal. For women with such lesions, missing a screening due to a disruption
400 is less harmful, which reduces the relative difference between primary cytology and primary HPV
401 screening in case of a disruption, and increases the effect of the second factor.

402

403 We also found that the relative excess rates of symptomatically-detected cancer projected for the
404 same delay period were higher for women overdue for screening compared with women who attend
405 screening according to guidelines. These relative increases were generally similar regardless of the
406 length of the delay period, as the underlying cases among the guidelines-compliant and overdue
407 women continued to accumulate with the length of delay. However, some delay-length trends were
408 observed (**Figure 2**), which may be due to the fact that the differences in the impact of the delay

409 between guidelines-compliant and under-screeners may become smaller in the case of a longer
410 delay (a longer screening delay increasingly becomes more impactful for guidelines-compliant
411 screeners as well). Delay-length differences are predominantly observed in MISCAN-Cervix, which
412 may be in part due to shorter dwell time assumptions. In contrast, for the Harvard and Policy1-
413 Cervix models that assume longer dwell times, the relative impacts between 1 and 5 year delay is
414 smaller.

415

416 Although our analysis was contextualized to the U.S., our results may still be generalizable to other
417 countries where cervical screening was disrupted such as the U.K., Ireland, New Zealand, and the
418 Netherlands where cervical screening was paused for 2-4 months (23-26). We considered
419 combinations of screening modality and screening frequency, some of which will be more applicable
420 to some countries than others. Our overarching findings that disruptions are likely to
421 disproportionately impact those who are already overdue for screening, and that under-screened
422 women are at higher risk than guidelines-compliant screeners affected by a temporary delay are
423 likely generalizable.

424

425 Importantly, self-collection of samples at home may provide a tool to reduce screening barriers and
426 facilitate outreach to under-screened people who are also most vulnerable to screening disruptions.
427 In the Netherlands, parts of Sweden, and recently Australia, self-sampling is available to all women,
428 and preliminary findings suggest this has facilitated rapid reintroductions to screening in the
429 Netherlands in the context of COVID-19 (24).

430

431 *Limitations and clinical relevance*

432 Despite the strength of consistent results from three established CISNET models, there are several
433 limitations that should be considered in interpreting our results. First, in the absence of detailed
434 information on cervical screening disruptions by screening frequency, we explored a range of
435 stylized scenarios that represent different combinations of screening behavior, disruption periods
436 and screening modalities.

437

438 We encountered several challenges as we planned this analysis, which we feel are worth describing
439 as they illustrate some of the limits of modeling in this context. The first is the scope of time over
440 which to consider outcomes. Attempting to assess screening delays over a short period presents
441 problems as short-term outcomes may not be representative of long-term health gains. For instance,
442 the occurrence of screening moments will always be associated with the incidence of cancer due to
443 the volume of screen detected disease. An analysis that attempted to consider changes in the
444 incidence of cancer within a finite period that includes resumption of screening will generate results
445 that are largely artefacts of the resumption of screening within the period of analysis rather than
446 fundamentally reflecting differences due to temporary extensions to the interval. Therefore, we
447 restricted the short-term analysis to the assessment of symptomatically detected cancers during a
448 finite delay period while the long-term analysis considered the net impact on CC risk given women's
449 lifetime screening participation.

450

451 Considering changes in the longer term required us to make assumptions about women's screening
452 behavior following the COVID-related delays as the impact of the temporary screen delays are
453 contingent on the subsequent screens they receive. Again, we encountered the potential for
454 modelling assumption to influence results. When screening eligibility is limited by an upper age
455 bound, i.e., age 65 years, the impact of a screen delay can depend heavily on what is assumed about
456 a woman's final screen (Summarized assumptions in **Appendix Tables A1 and A2**). For instance, a 1-
457 year delay to program for a woman following a 5-year interval would imply a final screen occurring
458 at age 61 rather than 65 in the 'no delay' scenario. In this instance, the model-projected changes in
459 long-term outcomes potentially reflect a missed final screen moment, rather than isolated only to

460 the extension of 1-year delay (increasing the screening interval temporarily from 5 to 6 years) (22,
461 27). Changes to future screening patterns maybe an overlooked secondary/long-term consequence
462 of this one-time COVID-19 disruption.

463

464 We did not project the impact of temporary disruptions on rarer outcomes such as cancer death as
465 the impact on incidence is an early indicator for mortality burden. We also did not consider
466 differences in underlying risk between various screening behavior groups (i.e., we assumed
467 differential cancer risk was a function of only screening behavior). If women who screen less
468 frequently also face a higher underlying risk of developing cancer, the differences in our projected
469 risks for delays to under-screener compared with guideline-compliant screeners may be
470 underestimated, providing additional support for a target outreach to under-screened women.

471

472 While our models do not explicitly simulate the impacts of specific factors including race and
473 ethnicity, poverty income level, education and insurance status, these characteristics are associated
474 with screening behavior, which we do capture in our simulation models. Furthermore, our
475 projections reflected the burden of cervical cancer assuming an average underlying natural history
476 risk of progression to cervical cancer, and we do not reflect the differential natural history for
477 immunocompromised women. Subsequently, our findings would not be generalizable to certain
478 groups facing greater background risk of developing cancer.

479

480 CONCLUSIONS

481 Our models predicted that the main driver of lifetime risk of cervical cancer is screening frequency
482 and screening modality, rather than temporary disruptions to screening; however, a disruption to
483 screening does not equally impact women with differential screening histories or screening
484 behaviors. Understanding and reaching under-screened women remains the most critical area of
485 focus, regardless of temporary disruptions.

486 **Data availability**

487 Supporting Information contained in the Supplementary Material of Burger et al. (20) provides
488 details on microsimulation model inputs, calibration to epidemiologic data, and calibration approach
489 in line with good modeling practice. This study involved modelling rather than direct analysis of
490 primary datasets. The current manuscript is a computational study, so no data have been generated
491 for this manuscript. The Cancer Intervention and Surveillance Modeling Network (CISNET)
492 (<https://cisnet.cancer.gov/>) Cervix model codes have been developed over decades, are proprietary
493 property, and cannot be provided by the authors at this time; however, CISNET-Cervix, under our
494 CISNET 'Model Accessibility' interest group is working to provide transparent and reproducible
495 modeling code for forthcoming projects ("C4"). Access to current code is possible only through
496 supervised training at each modeling group cite.

497

498 **Declaration of conflicting interests**

499 The author(s) declared the following potential conflicts of interest with respect to the research,
500 authorship, and/or publication of this article: Karen Canfell is the co-PI of an investigator-initiated
501 trial of CC screening, Compass, run by the VCS Foundation, which is a government-funded not-for-
502 profit charity. Neither KC nor her institution have received funding from industry for this or any
503 other research project. All other authors declare no conflicts. Emily A Burger receives salary support
504 from the Norwegian Cancer Society (#198073), and Megan A Smith receives salary support from the
505 National Health and Medical Research Council, Australia (APP1159491) and Cancer Institute NSW
506 (ECF181561). Matejka Rebolji: Public Health England provided funding for evaluation of various PHE
507 projects; member of various PHE advisory groups for cervical screening; attended meetings with
508 various HPV assay manufacturers; fee for lecture in the last four years from Hologic, paid to
509 employer.

510 REFERENCES

511

- 512 1. Fisher-Borne M, Isher-Witt J, Comstock S, Perkins RB. Understanding COVID-19 impact on
513 cervical, breast, and colorectal cancer screening among federally qualified healthcare centers
514 participating in "Back on track with screening" quality improvement projects. *Prev Med*.
515 2021;151:106681.
- 516 2. Mast C, Munoz del Rio A. Delayed cancer screenings—a second look. Verona, WI: Epic Health
517 Research Network; 2020. <https://ehrn.org/articles/delayed-cancer-screenings-a-second-lookexternal>
518 Accessed February 5, 2021.
- 519 3. Epic Research. "Troubling Cancer Screening Rates Still Seen Nearly Two Years Into the
520 Pandemic." Accessed May 5, 2022. Available at: [https://epicresearch.org/articles/troubling-cancer-](https://epicresearch.org/articles/troubling-cancer-screening-rates-still-seen-nearly-two-years-into-the-pandemic)
521 [screening-rates-still-seen-nearly-two-years-into-the-pandemic](https://epicresearch.org/articles/troubling-cancer-screening-rates-still-seen-nearly-two-years-into-the-pandemic) [
- 522 4. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive
523 values of cytology and human papillomavirus testing in cervical cancer screening: joint European
524 cohort study. *BMJ*. 2008;337:a1754.
- 525 5. Landy R, Sasieni PD, Mathews C, Wiggins CL, Robertson M, McDonald YJ, et al. Impact of
526 screening on cervical cancer incidence: A population-based case–control study in the United States.
527 *International Journal of Cancer*. 2020;147(3):887-96.
- 528 6. US Preventive Services Task Force. Screening for Cervical Cancer: US Preventive Services
529 Task Force Recommendation Statement. *JAMA*. 2018;320(7):674-86.
- 530 7. Cuzick J, Myers O, Hunt WC, Robertson M, Joste NE, Castle PE, et al. A Population-Based
531 Evaluation of Cervical Screening in the United States: 2008–2011. *Cancer Epidemiology Biomarkers*
532 *& Prevention*. 2014;23(5):765-73.
- 533 8. Johnson NL, Head KJ, Scott SF, Zimet GD. Persistent Disparities in Cervical Cancer Screening
534 Uptake: Knowledge and Sociodemographic Determinants of Papanicolaou and Human
535 Papillomavirus Testing Among Women in the United States. *Public Health Reports*. 2020;135(4):483-
536 91.
- 537 9. Wright JD, Chen L, Tergas AI, Melamed A, St. Clair CM, Hou JY, et al. Overuse of Cervical
538 Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014.
539 *JAMA Network Open*. 2021;4(4):e218373-e.
- 540 10. Wilson R, Quinn-Scoggins H, Moriarty Y, Hughes J, Goddard M, Cannings-John R, et al.
541 Intentions to participate in cervical and colorectal cancer screening during the COVID-19 pandemic:
542 A mixed-methods study. *Prev Med*. 2021;153:106826.
- 543 11. Castanon A, Rebolj M, Pesola F, Pearmain P, Stubbs R. COVID-19 disruption to cervical
544 cancer screening in England. *J Med Screen*. 2022:9691413221090892.
- 545 12. Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the Number of US Patients With Newly
546 Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. *JAMA*
547 *Network Open*. 2020;3(8):e2017267-e.
- 548 13. Ijzerman M, Emery J. Is a delayed cancer diagnosis a consequence of COVID-19? Published
549 April 3, 2020. Accessed September 10, 2021. [https://pursuit.unimelb.edu.au/articles/is-a-delayed-](https://pursuit.unimelb.edu.au/articles/is-a-delayed-cancer-diagnosis-a-consequence-of-covid-19)
550 [cancer-diagnosis-a-consequence-of-covid-19](https://pursuit.unimelb.edu.au/articles/is-a-delayed-cancer-diagnosis-a-consequence-of-covid-19).
- 551 14. Burger EA, Jansen EE, Killen J, Kok IMd, Smith MA, Sy S, et al. Impact of COVID-19-related
552 care disruptions on cervical cancer screening in the United States. *Journal of Medical Screening*.
553 2021;28(2):213-6.
- 554 15. Smith MA, Burger EA, Castanon A, de Kok I, Hanley SJB, Rebolj M, et al. Impact of disruptions
555 and recovery for established cervical screening programs across a range of high-income country
556 program designs, using COVID-19 as an example: A modelled analysis. *Prev Med*. 2021;151:106623.
- 557 16. Kim JJ, Simms KT, Killen J, Smith MA, Burger EA, Sy S, et al. Human Papillomavirus
558 Vaccination for Adults Aged 30-45 Years in the United States: A Cost-Effectiveness Analysis. *PLoS*
559 *Med*. 2021;18(3).

- 560 17. Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for
561 cervical cancer: US Preventive Services Task Force recommendation statement. *Jama*.
562 2018;320(7):674-86.
- 563 18. Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, et al. Adherence
564 patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV)
565 and cytology cotesting. *Prev Med*. 2018;109:44-50.
- 566 19. Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, et al. Projected time to elimination
567 of cervical cancer in the USA: a comparative modelling study. *The Lancet Public Health*.
568 2020;5(4):e213-e22.
- 569 20. Burger E, de Kok I, Groene E, Killen J, Canfell K, Kulasingam S, et al. Estimating the Natural
570 History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. *Journal*
571 *of the National Cancer Institute*. 2020:djz227.
- 572 21. de Kok IMCM, Burger EA, Naber SK, Canfell K, Killen J, Simms K, et al. The Impact of Different
573 Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum
574 Clinical Incidence Reduction (MCLIR) Methodology. *Medical decision making : an international*
575 *journal of the Society for Medical Decision Making*. 2020;40(4):474-82.
- 576 22. Wang J, Andrae B, Sundström K, Ploner A, Ström P, Elfström KM, et al. Effectiveness of
577 cervical screening after age 60 years according to screening history: Nationwide cohort study in
578 Sweden. *PLoS Med*. 2017;14(10):e1002414.
- 579 23. Public Health Agency. Restoration and Recovery of Paused Screening Programmes. 2020.
580 <http://www.cancerscreening.hscni.net/2228.htm>. Accessed 10th Sept 2021.
- 581 24. Clare A, Aitken, Ellen M.G. Olthof, Sylvia Kaljouw, Erik E.L. Jansen, Harry J. de Koning, Inge
582 M.C.M. de Kok. Evaluation of the Dutch Cervical Cancer Screening Programme 2017-2020. March
583 2022.
- 584 25. Campbell C, Sommerfield T, Clark GRC, Porteous L, Milne AM, Millar R, et al. COVID-19 and
585 cancer screening in Scotland: A national and coordinated approach to minimising harm. *Prev Med*.
586 2021;151:106606.
- 587 26. National Screening Service (21-03-2022) Covid-19 and cervical screening in Ireland: a
588 coordinated approach to minimising harm
589 <https://www.screeningservice.ie/news/news.php?idx=285>.
- 590 27. Castanon A, Rebolj M, Burger EA, De Kok IMCM, Smith MA, Hanley SJB, et al. Optimal
591 cervical screening COVID-19 recovery strategies in high-income countries depend on context of
592 current programme organisation. *The Lancet Public health*. 2021((in press)).

593

594 APPENDIX

595

596

597 1. Analytic screening assumptions

598 2. Additional results

599 **1. Analytic screening assumptions**

600

601 There were differences in how each modeling group applied screening. In order to isolate health
 602 outcomes to women disrupted in 2020, the Harvard and MISCAN-Cervix models assumed primary
 603 screening followed fixed intervals (so-called “age-based” screening) irrespective of possible follow-
 604 up testing which would normally affect the age at which a woman would next screen. In contrast,
 605 the Policy1-Cervix model allowed for dynamic primary screening based on time since last primary or
 606 follow-up screen, but isolated their model outcomes to the women who were delayed in 2020, i.e.,
 607 did not have previous positive results. Subsequently, the Policy-1-Cervix model reflects a marginally
 608 lower-risk cohort of women; however, while the absolute lifetime risk may be lower compared with
 609 the other two models, absolute changes in risk compared with their counterfactual of “no delay” will
 610 isolate the impact of delays.

611

612 In line with US guideline recommendations, all models assumed screening ended no later than age
 613 65 years (inclusive). Scenarios involving delays to screening shifted the timing of future screening in
 614 all groups other than annual screeners, and or some screening frequency and delay combinations,
 615 the delays to screening reduced the number of lifetime screens and changed the implied age of last
 616 screen (due to fixed screening intervals post-delay) (**Appendix Tables A1 and A2**). For example, for
 617 10-yearly screeners in the 1975 birth cohort (age 45 in 2020), a 1-year delay meant their last
 618 screening test occurred at age 56, 9 years earlier than in the ‘no delay’ scenario. In these same 10-
 619 yearly screeners, a 2- and 5-year delay shifted their age at last screen to age 57 and 60 years,
 620 respectively. Some of the added risk of the longer delay compared with a 1-year delay may be
 621 mitigated by the later screening end age in the longer delay scenarios (that end screening at age 57
 622 or 60, compared to age 56). Model-based analyses require making analytic assumptions about
 623 imperfect screening behavior and guidelines.

624

625 **Table A1.** Screening end age (lifetime number of screens) by birth cohort, screening frequency and
 626 delay duration.

627

		Annual	3-yearly*	5-yearly**	10-yearly
1965 (age 55 in 2020)	No delay	65 (45)	64 (15)	65 (9)	65 (5)
	1-year delay	65 (44)	65 (15)	61 (8)	56 (4)
	2-year delay	65 (43)	63 (14)	62 (8)	57 (4)
	5-year delay	65 (40)	63 (13)	65 (8)	60 (4)
1975 (age 45 in 2020)	No delay	65 (45)	63 (15)	65 (9)	65 (5)
	1-year delay	65 (44)	64 (15)	61 (8)	56 (4)
	2-year delay	65 (43)	65 (15)	62 (8)	57 (4)
	5-year delay	65 (40)	65 (14)	65 (8)	60 (4)
1985 (age 35 in 2020)	No delay	65 (45)	65 (15)	65 (8)	65 (5)
	1-year delay	65 (44)	63 (14)	61 (8)	56 (4)
	2-year delay	65 (43)	64 (14)	62 (8)	57 (4)
	5-year delay	65 (40)	64 (13)	65 (8)	60 (4)

*Guidelines-compliant screener with primary cytology-based screening;

**Guidelines-compliant screener with primary human papillomavirus (HPV) testing for women aged 30+ years.

628

629 **Table A2.** Example age at screen for the 1975 birth cohort without (highlighted in green) and with (highlighted in yellow) COVID-19-related delays, by
 630 screening frequency. Numbers under each delay are ages, bolded numbers are ages at which screening takes place, green highlight reflects no delay, and
 631 yellow highlights reflects a delay.

No Delay					1-year delay					2-year delay					5-year delay				
Year	Q1	Q3	Q5	Q10	Year	Q1	Q3	Q5	Q10	Year	Q1	Q3	Q5	Q10	Year	Q1	Q3	Q5	Q10
1996	21	21	21	21	1996	21	21	21	21	1996	21	21	21	21	1996	21	21	21	21
1997	22	22	22	22	1997	22	22	22	22	1997	22	22	22	22	1997	22	22	22	22
1998	23	23	23	23	1998	23	23	23	23	1998	23	23	23	23	1998	23	23	23	23
1999	24	24	24	24	1999	24	24	24	24	1999	24	24	24	24	1999	24	24	24	24
2000	25	25	25	25	2000	25	25	25	25	2000	25	25	25	25	2000	25	25	25	25
2001	26	26	26	26	2001	26	26	26	26	2001	26	26	26	26	2001	26	26	26	26
2002	27	27	27	27	2002	27	27	27	27	2002	27	27	27	27	2002	27	27	27	27
2003	28	28	28	28	2003	28	28	28	28	2003	28	28	28	28	2003	28	28	28	28
2004	29	29	29	29	2004	29	29	29	29	2004	29	29	29	29	2004	29	29	29	29
2005	30	30	30	30	2005	30	30	30	30	2005	30	30	30	30	2005	30	30	30	30
2006	31	31	31	31	2006	31	31	31	31	2006	31	31	31	31	2006	31	31	31	31
2007	32	32	32	32	2007	32	32	32	32	2007	32	32	32	32	2007	32	32	32	32
2008	33	33	33	33	2008	33	33	33	33	2008	33	33	33	33	2008	33	33	33	33
2009	34	34	34	34	2009	34	34	34	34	2009	34	34	34	34	2009	34	34	34	34
2010	35	35	35	35	2010	35	35	35	35	2010	35	35	35	35	2010	35	35	35	35
2011	36	36	36	36	2011	36	36	36	36	2011	36	36	36	36	2011	36	36	36	36
2012	37	37	37	37	2012	37	37	37	37	2012	37	37	37	37	2012	37	37	37	37
2013	38	38	38	38	2013	38	38	38	38	2013	38	38	38	38	2013	38	38	38	38
2014	39	39	39	39	2014	39	39	39	39	2014	39	39	39	39	2014	39	39	39	39
2015	40	40	40	40	2015	40	40	40	40	2015	40	40	40	40	2015	40	40	40	40
2016	41	41	41	41	2016	41	41	41	41	2016	41	41	41	41	2016	41	41	41	41
2017	42	42	42	42	2017	42	42	42	42	2017	42	42	42	42	2017	42	42	42	42
2018	43	43	43	43	2018	43	43	43	43	2018	43	43	43	43	2018	43	43	43	43
2019	44	44	44	44	2019	44	44	44	44	2019	44	44	44	44	2019	44	44	44	44
2020	45	45	45	45	2020	45	45	45	45	2020	45	45	45	45	2020	45	45	45	45
2021	46	46	46	46	2021	46	46	46	46	2021	46	46	46	46	2021	46	46	46	46
2022	47	47	47	47	2022	47	47	47	47	2022	47	47	47	47	2022	47	47	47	47
2023	48	48	48	48	2023	48	48	48	48	2023	48	48	48	48	2023	48	48	48	48
2024	49	49	49	49	2024	49	49	49	49	2024	49	49	49	49	2024	49	49	49	49
2025	50	50	50	50	2025	50	50	50	50	2025	50	50	50	50	2025	50	50	50	50
2026	51	51	51	51	2026	51	51	51	51	2026	51	51	51	51	2026	51	51	51	51
2027	52	52	52	52	2027	52	52	52	52	2027	52	52	52	52	2027	52	52	52	52
2028	53	53	53	53	2028	53	53	53	53	2028	53	53	53	53	2028	53	53	53	53
2029	54	54	54	54	2029	54	54	54	54	2029	54	54	54	54	2029	54	54	54	54
2030	55	55	55	55	2030	55	55	55	55	2030	55	55	55	55	2030	55	55	55	55


2031 **56** 56 56 56
2032 **57** **57** 57 57
2033 **58** 58 58 58
2034 **59** 59 59 59
2035 **60** **60** **60** 60
2036 **61** 61 61 61
2037 **62** 62 62 62
2038 **63** **63** 63 63
2039 **64** 64 64 64
2040 **65** 65 **65** **65**
2041 66 66 66 66

2031 **56** 56 **56** **56**
2032 **57** 57 57 57
2033 **58** **58** 58 58
2034 **59** 59 59 59
2035 **60** 60 60 60
2036 **61** **61** **61** 61
2037 **62** 62 62 62
2038 **63** 63 63 63
2039 **64** **64** 64 64
2040 **65** 65 65 65
2041 66 66 66 66

2031 **56** **56** 56 56
2032 **57** 57 **57** **57**
2033 **58** 58 58 58
2034 **59** **59** 59 59
2035 **60** 60 60 60
2036 **61** 61 61 61
2037 **62** **62** **62** 62
2038 **63** 63 63 63
2039 **64** 64 64 64
2040 **65** **65** 65 65
2041 66 66 66 66

2031 **56** **56** 56 56
2032 **57** 57 57 57
2033 **58** 58 58 58
2034 **59** **59** 59 59
2035 **60** 60 **60** **60**
2036 **61** 61 61 61
2037 **62** **62** 62 62
2038 **63** 63 63 63
2039 **64** 64 64 64
2040 **65** **65** **65** 65
2041 66 66 66 66

632 **Figure A1.** Schematic of short-term cancer burden calculations*



*Modeling outputs provided cancer rates on an annual (yearly) basis; therefore, a small proportion of 'delay-related' cases are not captured (e.g., a one-year disruption that started March 2020 would continue into February 2021). Our model-based outputs would, therefore, underestimate a small proportion of cancer-burden; however, these underestimates would be captured similarly in both the numerator and denominator of the RR, likely underestimating the RR). Abbreviations: Qx, primary screening interval; dx, delay period; X, a new screen occurs

633

634 **2. Additional results**

635

636 **Table A3.** Relative rate ratios and accumulated incidence rates per 100,000 women for each
637 screening frequency and delay scenario

Screening frequency	1-yr delay	2-yr delay	5-year delay
<i>Policy1-Cervix</i>			
5-yearly screener (cytology)	1.40 = 4.94 / 3.58	1.44 = 10.05 / 7.00	1.57 = 30.03 / 19.10
10-yearly screener (cytology)	3.10 = 11.06 / 3.58	3.35 = 23.45 / 7.00	3.34 = 63.72 / 19.10
10-yearly screener (HPV)	2.26 = 7.36 / 3.26	2.48 = 15.31 / 6.18	2.54 = 42.41 / 16.67
<i>MISCAN-Cervix</i>			
5-yearly screener (cytology)	2.78 = 3.00 / 1.08	2.28 = 6.41 / 2.81	1.99 = 22.09 / 11.08
10-yearly screener (cytology)	6.97 = 7.54 / 1.08	5.73 = 16.11 / 2.81	4.15 = 45.97 / 11.08
10-yearly screener (HPV)	3.91 = 6.08 / 1.55	3.67 = 13.08 / 3.56	2.97 = 38.84 / 13.09
<i>Harvard</i>			
5-yearly screener (cytology)	1.8 = 9.64 / 5.37	1.74 = 17.69 / 10.15	1.64 = 45.97 / 27.96
10-yearly screener (cytology)	3.8 = 20.39 / 5.37	3.64 = 36.94 / 10.15	3.19 = 89.29 / 27.96
10-yearly screener (HPV)	3.61 = 10.74 / 2.98	3.58 = 19.51 / 5.45	3.69 = 46.83 / 12.68

Relative rate ratio is calculated as the accumulated incidence rate per 100,000 women during a delay period for a give screening history divided by the accumulated incidence rate per 100,000 women during the same delay period among guidelines-compliant screeners. Incidence rates are the average across the three birth cohorts. 3-yearly cytology screening is considered guidelines-compliant screening; 5-yearly HPV screening is considered guidelines compliant.

638

639

640

641 **Table A4.** Percentage reduction in average (across the 1965, 1975, and 1985 birth cohorts) lifetime
 642 risk of cancer compared with no screening

		Screening frequency			
		Annual	3-yearly	5-yearly	10-yearly
Primary cytology-based screening					
<i>Harvard</i>					
	No delay	88.4 %	79.9 %	71.4 %	56.3 %
	1-year delay	88.5 %	80.0 %	70.9 %	55.3 %
	2-year delay	88.4 %	79.5 %	70.5 %	54.9 %
	5-year delay	87.9 %	78.4 %	69.3 %	53.4 %
<i>MISCAN-Cervix</i>					
	No delay	85.1 %	72.1 %	62.1 %	48.4 %
	1-year delay	85.0 %	71.7 %	60.2 %	44.7 %
	2-year delay	84.7 %	71.2 %	59.9 %	44.9 %
	5-year delay	83.1 %	69.1 %	58.8 %	43.9 %
<i>Policy1-Cervix</i>					
	No delay	87.7 %	86.5 %	84.5 %	75.9 %
	1-year delay	87.8 %	86.3 %	82.3 %	71.9 %
	2-year delay	87.7 %	85.8 %	82.5 %	71.9 %
	5-year delay	86.8 %	85.1 %	82.5 %	71.3 %
Primary HPV-based screening					
<i>Harvard</i>					
	No delay	92.6 %	89.3 %	86.7 %	77.8 %
	1-year delay	92.6 %	89.4 %	86.6 %	77.1 %
	2-year delay	92.6 %	89.4 %	86.6 %	76.7 %
	5-year delay	92.6 %	89.2 %	86.4 %	75.0 %
<i>MISCAN-Cervix</i>					
	No delay	94.0 %	84.2 %	74.8 %	58.0 %
	1-year delay	93.9 %	83.8 %	72.3 %	53.5 %
	2-year delay	93.6 %	83.2 %	72.3 %	53.5 %
	5-year delay	92.3 %	81.0 %	70.8 %	51.8 %
<i>Policy1-Cervix</i>					
	No delay	90.9 %	90.4 %	90.1 %	86.6 %
	1-year delay	90.9 %	90.4 %	88.7 %	82.7 %
	2-year delay	91.0 %	90.1 %	89.0 %	82.8 %
	5-year delay	91.0 %	90.0 %	89.2 %	82.6 %

643

644